ClinVar Miner

Submissions for variant NM_138694.4(PKHD1):c.5360G>T (p.Cys1787Phe)

gnomAD frequency: 0.00002  dbSNP: rs367970695
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Institute for Human Genetics and Genomic Medicine, Uniklinik RWTH Aachen RCV001751808 SCV001994883 uncertain significance Polycystic kidney disease 4 2021-11-02 criteria provided, single submitter clinical testing The detected change is reported in the dbSNP database (dbSNP150, status October 28, 2021) with the designation rs367970695. In gnomAD it is listed with a frequency of 0.001769% (5/282592) (as of October 28, 2021). In the literature it has already been described in a patient with ARPKD in combination with a pathogenic variant (Losekoot et al., 2005). In terms of bio-informatics, the change is classified as “likely disease causing” (PolyPhen2, Mutation Taster, SIFT). Based on the current state of knowledge, the variant is to be classified as a "variant of uncertain significance" (ACMG criteria).
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003323914 SCV004029910 uncertain significance not specified 2023-07-28 criteria provided, single submitter clinical testing Variant summary: PKHD1 c.5360G>T (p.Cys1787Phe) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 251208 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.5360G>T has been reported in the literature as a compound heterozygous genotype in two individuals affected with Polycystic Kidney And Hepatic Disease and as an uninformative genotype (i.e. zygosity not specified) or in the heterozygous state in several other affected individuals (e.g. Losekoot_2005, Bergmann_2005, Burgmaier_2021). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 15698423, 33940108, 16133180). Two submitters have cited clinical-significance assessments for this variant to ClinVar after 2014 and both classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.
GeneDx RCV003329410 SCV004036936 uncertain significance not provided 2023-09-08 criteria provided, single submitter clinical testing Observed heterozygous with no other PKHD1 variant in a family with polycystic kidney disease in published literature (Bergmann C et al., 2005); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 8740301, 15698423, 16133180, 33940108)
Baylor Genetics RCV001751808 SCV004202244 likely pathogenic Polycystic kidney disease 4 2023-10-14 criteria provided, single submitter clinical testing
Invitae RCV003502598 SCV004275660 likely pathogenic Autosomal recessive polycystic kidney disease 2024-01-10 criteria provided, single submitter clinical testing This sequence change replaces cysteine, which is neutral and slightly polar, with phenylalanine, which is neutral and non-polar, at codon 1787 of the PKHD1 protein (p.Cys1787Phe). This variant is present in population databases (rs367970695, gnomAD 0.003%). This missense change has been observed in individuals with polycystic kidney disease (PMID: 15698423, 16133180, 33940108). ClinVar contains an entry for this variant (Variation ID: 1255539). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PKHD1 protein function with a positive predictive value of 95%. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Laboratory of Gastroenterology and Hepatology, Radboud University Medical Center RCV001844868 SCV001876979 uncertain significance Autosomal dominant polycystic kidney disease 2021-09-01 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.